Table 2:
Demographic information and the treatment data of included articles
| No | Reference | Country | Number of Patients | Age (yr) | Male/Female | Variables | Dosage | Duration of Therapy |
|---|---|---|---|---|---|---|---|---|
| 1 | (22 ) | Australia | 79 | 40.69 | 10/69 | GSRS, DASS-21, intestinal microbial profile | 500 mg once daily | Eight weeks |
| 2 | (19 ) | Australia | 43 | 50 | 10/33 | Intestinal permeability and gut microbiota profile | 10 g/day of the mixture containing curcumin | Four weeks |
| 3 | (20 ) | Israel | 22 | 54.5 | 6/16 | QoL, IBSS, IBS symptom | Four oral tablets/day containing 500 mg curcumin | Ten weeks |
| 4 | (18 ) | Italy, Belgium | 211 | 51±17 | 63/148 | IBSS, QoL, number of pain locations | The mixture containing 42 mg of curcumin | Ten weeks |
| 5 | (16 ) | Germany, Malaysia | 90 | 18–70 | 27/63 | Pain and discomfort | The mixture containing 330 mg of curcuminoids | Eight weeks |
| 6 | (21 ) | Germany, Australia | 32 | 50.3±11. 9 | 13/19 | IBSS, QoL, anxiety, depression, compliance and safety | The mixture containing turmeric twice daily | Four weeks |
| 7 | (17 ) | Italy | 116 | 18–66 | 44/77 | IBSS, abdominal pain | The mixture containing 42 mg curcumin Two capsules/day | Four weeks |
| 8 | (23 ) | Russia | 50 | - | - | Abdominal pain, bloating and feeling of incomplete bowel emptying, frequency of bowel movement, QoL | The mixture containing 10 mg curcumin | Two weeks |
| 9 | (15 ) | UK | 207 | - | 62/145 | IBS prevalence, symptom-related QoL, effectiveness | 72–144 mg/day of turmeric | Eight weeks |
IBSS: IBS Severity, GSRS: Gastrointestinal Symptom Rating Scale, DASS-21: Depression Anxiety and Stress Scale - 21, QoL: Quality of Life.